title: PDE-5 Inhibitors for BPH-Associated LUTS.
abstract: Lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH-LUTS) are a highly prevalent problem, and with considerable burden to quality of life. Evidence has emerged that a strong correlation exists in men suffering both BPH-LUTS and erectile dysfunction (ED). Phosphodiesterase type 5 inhibitors (PDE5i) have been shown to be highly effective in treating ED and more recently there is evidence that men with LUTS also benefit. In this review article we discuss the common pathogenic pathways of ED and LUTS, the scientific basis of PDE5i use, the efficacy of PDE5i in LUTS either as monotherapy or in combination with other established medications used in LUTS.
authors.forename: Philip
authors.initials: P
authors.lastname: Brousil
authors.forename: Majid
authors.initials: M
authors.lastname: Shabbir
authors.forename: E
authors.initials: E
authors.lastname: Zacharakis
authors.affiliation: Department of Urology, Guy's and St Thomas' NHS Trust, King's Health Partners, London, UK. arun.sahai@gstt.nhs.uk.
authors.forename: Arun
authors.initials: A
authors.lastname: Sahai
mesh_terms: D007172:Erectile Dysfunction / Q000188:drug therapy / Q000503:physiopathology; D006801:Humans; D059411:Lower Urinary Tract Symptoms / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D008297:Male; D058986:Phosphodiesterase 5 Inhibitors / Q000627:therapeutic use*; D011470:Prostatic Hyperplasia / Q000150:complications* / Q000188:drug therapy; D014563:Urodynamics / Q000187:drug effects
chemical_list: D058986:Phosphodiesterase 5 Inhibitors